Zscaler to Webcast Analyst Day on Tuesday, September 17, 2019
Get Alerts ZS Hot Sheet
Join SI Premium – FREE
SAN JOSE, Calif., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced it will host its Analyst Day on Tuesday, September 17 in Las Vegas, NV. The event will take place during the company’s annual Zenith Live Cloud Summit.
Attendance for this event is by invitation only. The event will be webcast live at 11:30 a.m. PT and archived on the Investor Relations section of Zscaler’s website at https://ir.zscaler.com/. Listeners may log on to the presentation under the “Events & Presentations” section and select “Zscaler 2019 Analyst Day” to participate.
About Zscaler
Zscaler™ (NASDAQ: ZS) enables the world’s leading organizations to securely transform their networks and applications for a mobile and cloud-first world. Its flagship services, Zscaler Internet Access™ and Zscaler Private Access™, create fast, secure connections between users and applications, regardless of device, location, or network. Zscaler services are 100 percent cloud-delivered and offer the simplicity, enhanced security, and improved user experience that traditional appliances are unable to match. Used in more than 185 countries, Zscaler operates a multi-tenant distributed cloud security platform, protecting thousands of customers from cyberattacks and data loss. Learn more at zscaler.com or follow us on Twitter @zscaler.
Zscaler™, Zscaler Internet Access™, Zscaler Private Access™, ZIA™ and ZPA™ are either (i) registered trademarks or service marks or (ii) trademarks or service marks of Zscaler, Inc. in the United States and/or other countries. Any other trademarks are the property of their respective owners.
Investor Relations Contact:Bill Choi, CFAVice President, Investor Relations408-816-1478[email protected]
Source: Zscaler, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enjoin Reports 923% Average ROI Delivered in Q1 2026
- Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN
- Telarvo Delivers 4-Port Industrial GSM Gateway as Cloud Dependency Risks Reshape Enterprise Telecom Strategies
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share